BUY

Owns many homebuilders over the years and done very well. TOL is the highest-quality builder in the US, attracting the highest demographic. Rich. 25% of their buyers pay with cash. TOL now offers homes to a poorer demographic. They trade at a reasonable PE and interest rates are coming down. Also, the US is 5 million home short.

BUY

Was a past pick of his. Shares have been bumpy for fears that Trump will impose tariffs on solar panels and he doesn't like green energy, though there's bi-partisan support for solar energy. FSLR is the only real option for the US, so FSLR is a fine position. Shares will be bumpy thought. Buy for the long term.

DON'T BUY

All healthcare companies starting in pharmacies have been vertically segments like insurance, but they've had a tough time, because pharmacies are low-margin and getting tougher. Also, governments are getting more involved in drug pricing. Thirdly, post Covid medical procedures remain high which also squeezes margins. He exited CVS 6-8 months ago.

TOP PICK

Long been in the doghouse, but the new CEO has pared foreign exposure and made the company more efficient. Remain cheap at a 36% discount to tangible book value. They will rapidly boost earnings. 

(Analysts’ price target is $72.21)
TOP PICK

A small cap making homebuilding products like garage doors. A play on homebuilding; there's a housing shortage. Low PE, but profitable.

(Analysts’ price target is $87.40)
TOP PICK

He hasn't owned this in decades. He bought it in the recent tech dip. Trades near 30x PE, attractive historically. Are heavily into AI. Grows at 15-17% annually in profits and cash flow.

(Analysts’ price target is $499.32)